Condition
Nonobstructive Hypertrophic Cardiomyopathy clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Nonobstructive Hypertrophic Cardiomyopathy clinical trials that are recruiting, at sites in 2 countries (most in United States (1), South Korea (1)). By phase: Phase 1 (1), Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
HTX-001: a first-in-human test to see if this daily shot is safe for adults with nonobstructive hypertrophic cardiomyopathy
This study tests multiple doses of HTX-001, an injectable antisense therapy, to see if it is safe and how it behaves in the body for adults with nonobstructive hypertrophic cardiomyopathy already on standard care.
-
Enavogliflozin for treating diastolic dysfunction in nonobstructive hypertrophic cardiomyopathy
This study is testing if the medication enavogliflozin can help people with nonobstructive hypertrophic cardiomyopathy feel better and improve their heart function compared to a placebo over 24 weeks.
Quick answers
How many Nonobstructive Hypertrophic Cardiomyopathy clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.